Management of glioblastoma: a perspective from Nigeria
Editorial Commentary on Evolving Landscape of the Management of Glioblastoma

Management of glioblastoma: a perspective from Nigeria

James A. Balogun1,2, Adefisayo A. Adekanmbi2

1Division of Neurosurgery, Department of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria; 2Department of Neurosurgery, University College Hospital, Ibadan, Nigeria

Correspondence to: James A. Balogun. Division of Neurosurgery, Department of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria. Email: jabalogun@com.ui.edu.ng; jamesabalogun@gmail.com.

Submitted Jan 13, 2020. Accepted for publication Feb 03, 2020.

doi: 10.21037/cco.2020.02.06


Introduction

Glioblastoma (GBM), a grade IV astrocytic tumor, is the most common malignant primary brain tumor and is also described as one of the most aggressive tumor with remarkable a propensity for proliferation. There have been considerable efforts, at understanding the pathophysiology of the tumor, and identifying treatment targets. However, most of these efforts have not yielded the hoped for results, with the 2005 adapted Stupp protocol, still the standard of care for newly diagnosed GBM (1). The prognosis of the disease continues to be poor despite our growing understanding of predictive and prognostic markers.


Epidemiology

GBM is the most common adult glial tumor worldwide. There is a significant variation in the epidemiology of GBM in different regions of the world, with a clear predominance amongst Caucasians compared with the African-Americans (2). Reliable data on the occurrence of GBM in Sub-Saharan Africa and indeed Nigeria is scarce. This may be attributed to a paucity of tumor registries, pre-operative deaths from untreated, symptomatic, large tumors due to cultural and religious beliefs and limited neuropathological diagnosis resulting from a dearth of neuropathologists or general pathologists familiar with the diagnosis of the disease.

Published data, from recent series of small cohort of patients, suggest that meningioma is the most common intracranial tumor among Nigerians (3-5). GBM had been previously reported as uncommon by the forebears of Nigerian neurosurgery (6), and even more so in a report years after this submission (7). There are however more recent reports, that suggest a gradual increase in diagnosis of GBM among Nigerians and GBM reported to be the most common type of glioma as it is in other parts of the world (8,9). The Nigerian patient, presumably presents at a younger age, compared to Caucasians, with advanced disease (9). The reported low incidence of the disease in Nigeria may also be impacted by the absent or non-documentation of some of the established risk factors for GBM such as exposure to ionizing radiations, and low report of familial syndromes such as Lynch and Li-Fraumeni syndromes.


Clinical presentation and diagnosis

The patients in Nigeria usually present late, with significant tumor burden that directly impacts on prognosis (10). Symptomatology are not different from those seen in other populations, with most of the patients presenting with headaches, seizures and focal neurologic deficits. The imaging diagnosis of GBM has improved over the years, with the availability of increasing number of privately driven, high-field MRI machines within the country. Studies are still mainly anatomic, with limited physiologic and functional studies.


Management and outcome

The imaging diagnosis of a possible GBM warranting a surgical consult, should ordinarily lead to the discussion of the case at a multidisciplinary tumor board, to forge a treatment pathway for the patient. This also facilitates the tracking of the patient treatment. Most centers where GBM is managed in Nigeria do not however have real time tumor boards, often due to lack of appropriate expertise. This makes a case for virtual tumor board which is worth utilizing, especially in the context of having expert views from high volume centers. This concept may be challenged by dearth of infrastructure, but surely, it can be overcome by the currently available technological advances. There is however a significant amount of discussion of patients’ care, using real time instant messaging media and e-mails. The ethical issue of confidentiality of patient’s health information will continue to evolve but with de-anonymized data, the risk of exposure for patient becomes low.

The standard of care of patients with GBM worldwide, includes surgical resection, followed by the Stupp protocol (11), which has resulted in documented increase in the overall survival (12). There is also a strong suggestion that survival is associated with the race of the patients; being highest in Asians and pacific islanders and lowest in non-Hispanic whites in the United States (13,14). It has also been observed that participation in clinical trials, which is non-existent in our environment, also improves survival in the patients (1). The outcome of patients with GBM in Nigeria however appears to be poorer than seen in other climes and this is due to multiple factors influencing the care of our patients (8).

The extent of resection of GBM has been validated to influence both the overall survival and progression free survival (15,16). There has been advocacy for supra-total resection and lobectomy for temporal GBM (17,18) to further improve prognosis. However varying extents of resections; gross total resection, subtotal resection and surgical biopsy, were reported in the Enugu series in Nigeria, with a debatable conclusion that the choice of surgery did not affect outcome of care (7). We recognize that achieving gross total resection without significant morbidity and compromise of the quality of life of the patient, is limited by the large size of the tumors and the advanced stage of the disease due to delayed presentation from varied reasons (8). Most Nigerian neurosurgical units do not have established protocols for prioritizing the surgical care of patients with GBM, a situation that is complicated by the out-of-pocket payment for treatment and low coverage of the national health insurance scheme, which also has a limited coverage for cancer treatment. While the fatalistic ideas of just committing the patients with GBM to palliative or end of life care has significantly waned among Nigerian neurosurgeons, the capacity of the surgeons to achieve safe maximal resections is sub-optimal due to the limited or non-availability of the surgical armamentarium that have been developed over the years to improve safety and reduce morbidity. Such innovations include awake craniotomy and brain mapping, fluorescence guided resections, and intra-operative MRI/Ultrasound scan (19-24). The latter, which has been previously described as the ‘poor man’s neuronavigation’, has undergone refinement in its application in neuro-oncology, particularly in GBM surgery. However, it still hasn’t found a predominant position in the operating rooms within the country despite its versatility and lower cost, mainly due to lack of familiarity with its use and possibly limited availability of the appropriate probes. Thus, the extent of the surgery not only depends on the presentation of the patient but also on the perspectives of the surgeon.

The Stupp protocol has remained the standard of care for the post-operative care of newly diagnosed GBM (1,25), though with different suggestions of modifications such as the ‘super-early’ initiation of temozolomide (26). The challenge of the post-operative care of these patients in Nigeria is not predicated on just the high cost of temozolomide, especially when considered in the background of a predominant out-of-pocket healthcare payment, by a majorly poor population with a low minimum wage (27,28), but also on its availability. Thus, only a small percentage of patients can afford or maintain the required chemotherapy cycles. Other drugs such as bevacizumab have not demonstrated the hoped results in newly diagnosed GBM. Tumor treating fields (TTFields), which have been approved and gained acceptance, as an addition to maintenance temozolomide, for the treatment of newly diagnosed GBM, with resultant improvement in overall survival and progression free survival (29), is not available within the Nigerian healthcare system.

Most of the definitive pathologic diagnosis of GBM in Nigeria are still based on histopathology results utilizing hematoxylin and eosin staining (7). The average Nigerian patient, does not therefore, benefit from the predictive and prognostic marker evaluations of tissue specimens, a situation that is almost a sin-qua-non with the 2016 WHO modification of the brain tumor classification (30,31). Efforts are however being directed at accessing non-generic kits for these markers to reduce the cost and thus make them more available as part of the patients’ pathological evaluation. The post-operative care is further complicated by the limited availability of, and skewed distribution of radiotherapy machines. These are essentially cobalt machines but a few conformal radiotherapy machines and linear accelerator (LiNAC) have become available more recently with different downtimes between machines (32,33). The challenge created by delayed access to post-op chemotherapy and radiotherapy is early recurrence or progression of the disease, thus, impacting on mortality and morbidity.


Way forward

With a paucity of specialists in neuro-oncology, which is a reflection of the overall shortage in the number of trained neurosurgeons, neuroradiologists, nurses and palliative care specialists in Nigeria (34), making a case for sub-specialty training in neuro-oncology should not be viewed as a luxury, but a fundamental tool, that will help refine, strengthen and direct the care of the GBM patients. Continuing advocacy and engagement with the government and stakeholders on the need for improving access to radiotherapy and chemotherapy will be important. Utilizing technology for virtual tumor boards and low cost intra-operative ultrasound will further improve the care of these patients.


Conclusions

The obvious disparity in the treatment of the Nigerian patients with GBM and those in high income economies, with resultant poorer outcomes, can be reduced. This can be achieved with capacity building in neuro-oncology, increasing advocacy for early detection and presentation, leveraging on technological advancement, as well as increasing stakeholder and government’s involvement in the provision of facilities for the care of these patients. These will be important keys to improving their survival.


Acknowledgments

Funding: None.


Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editor (Rimas V. Lukas) for the series “The Evolving Landscape of the Management of Glioblastoma” published in Chinese Clinical Oncology. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cco.2020.02.06). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Lukas RV, Wainwright DA, Ladomersky E, et al. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park) 2019;33:91-100. [PubMed]
  2. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, et al. EPID-20. Trends in glioblastoma outcomes over time, geographic location and type of intervention. Neuro Oncol 2019;21:vi78-9. [Crossref]
  3. Ndubuisi CA, Ohaegbulam SC, Iroegbu LU, et al. Histologically Confirmed Intracranial Tumors Managed at Enugu, Nigeria. J Neurosci Rural Pract 2017;8:585-90. [Crossref] [PubMed]
  4. Soyemi SS, Oyewole OO. Spectrum of intracranial tumours in a tertiary health carefacility: our findings. Pan Afr Med J 2015;20:24. [Crossref] [PubMed]
  5. Idowu O, Akang EEU, Malomo A. Symptomatic primary intracranial neoplasms in Nigeria, West Africa. Neurol Sci (Turkish) 2007;24:212-8.
  6. Odeku EL, Adeloye A. Gliomas of the brain among Nigerians. Afr J Med Med Sci 1976;5:31-3. [PubMed]
  7. Olasode BJ, Shokunbi MT, Aghadiuno PU. Intracranial neoplasms in Ibadan, Nigeria. East Afr Med J 2000;77:4-8. [PubMed]
  8. Ndubuisi CA, Mezue WC, Nzegwu M, et al. The challenges of management of high-grade gliomas in Nigeria. J Neurosci Rural Pract 2017;8:407-11. [Crossref] [PubMed]
  9. Ndubuisi CA, Ohaegbulam SC, Chikani MO, et al. Some characteristics of gliomas managed at a neurosurgery centre in Nigeria. Niger Postgrad Med J 2017;24:44-7. [Crossref] [PubMed]
  10. Idowu OE, Apemiye RA. Delay in presentation and diagnosis of adult primary intracranial neoplasms in a tropical teaching hospital: a pilot study. Int J Surg 2009;7:396-8. [Crossref] [PubMed]
  11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. [Crossref] [PubMed]
  12. Preusser M, de Ribaupierre S, Wöhrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011;70:9-21. [Crossref] [PubMed]
  13. Ostrom QT, Cote DJ, Ascha M, et al. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 2018;4:1254-62. [Crossref] [PubMed]
  14. Patel NP, Lyon KA, Huang JH. The effect of race on the prognosis of the glioblastoma patient: a brief review. Neurol Res 2019;41:967-71. [Crossref] [PubMed]
  15. Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2016;2:1460-9. [Crossref] [PubMed]
  16. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8. [Crossref] [PubMed]
  17. Schneider M, Potthoff AL, Keil VC, et al. Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. J Neurooncol 2019;145:143-50. [Crossref] [PubMed]
  18. Duffau H. Is supratotal resection of glioblastoma in noneloquent areas possible? World Neurosurg 2014;82:e101-3. [Crossref] [PubMed]
  19. Gandhi S, Tayebi Meybodi A, Belykh E, et al. Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis. Front Oncol 2019;9:620. [Crossref] [PubMed]
  20. Gerritsen JKW, Arends L, Klimek M, et al. Impact of intraoperative stimulation mapping on high-grade glioma surgery outcome: a meta-analysis. Acta Neurochir (Wien) 2019;161:99-107. [Crossref] [PubMed]
  21. Hervey-Jumper SL, Berger MS. Technical nuances of awake brain tumor surgery and the role of maximum safe resection. J Neurosurg Sci 2015;59:351-60. [PubMed]
  22. Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol 2019;141:479-86. [Crossref] [PubMed]
  23. Bander ED, Magge R, Ramakrishna R. Advances in glioblastoma operative techniques. World Neurosurg 2018;116:529-38. [Crossref] [PubMed]
  24. Del Bene M, Perin A, Casali C, et al. Advanced ultrasound imaging in glioma surgery: beyond gray-scale B-mode. Front Oncol 2018;8:576. [Crossref] [PubMed]
  25. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66. [Crossref] [PubMed]
  26. Jiang H, Zeng W, Ren X, et al. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study. J Neurooncol 2019;144:127-35. [Crossref] [PubMed]
  27. Uyl-de Groot CA, Stupp R, van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res 2009;9:235-41. [Crossref] [PubMed]
  28. Balogun JA, Kayode Idowu O, Obanisola Malomo A. Challenging the myth of outpatient craniotomy for brain tumor in a Sub-Saharan African setting: a case series of two patients in Ibadan, Nigeria. Surg Neurol Int 2019;10:71. [Crossref] [PubMed]
  29. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017;318:2306-16. [Crossref] [PubMed]
  30. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20. [Crossref] [PubMed]
  31. Banan R, Hartmann C. The new WHO 2016 classification of brain tumors-what neurosurgeons need to know. Acta Neurochir (Wien) 2017;159:403-18. [Crossref] [PubMed]
  32. Wroe LM, Ige TA, Asogwa OC, et al. Comparative analysis of radiotherapy linear accelerator downtime and failure modes in the UK, Nigeria and Botswana. Clin Oncol (R Coll Radiol) 2020;32:e111-8. [Crossref] [PubMed]
  33. Nwankwo KC, Dawotola DA, Sharma V. Radiotherapy in Nigeria: current status and future challenges. West Afr J Radiol 2013;20:84. [Crossref]
  34. Adekanmbi A, Peters KB, Razis E, et al. Neuro-oncology research in Nigeria: a great untapped potential. World Neurosurg 2019; Epub ahead of print. [Crossref] [PubMed]
Cite this article as: Balogun JA, Adekanmbi AA. Management of glioblastoma: a perspective from Nigeria. Chin Clin Oncol 2021;10(4):43. doi: 10.21037/cco.2020.02.06